CA2863106A1 - Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients - Google Patents

Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients Download PDF

Info

Publication number
CA2863106A1
CA2863106A1 CA2863106A CA2863106A CA2863106A1 CA 2863106 A1 CA2863106 A1 CA 2863106A1 CA 2863106 A CA2863106 A CA 2863106A CA 2863106 A CA2863106 A CA 2863106A CA 2863106 A1 CA2863106 A1 CA 2863106A1
Authority
CA
Canada
Prior art keywords
hbv
subject suffering
susceptible
identifying
immunocomplexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2863106A
Other languages
English (en)
French (fr)
Inventor
Ursula Klause
Berthold HIPP
Veit Peter Grunert
Barbara Upmeier
Uri Lopatin
Annikki DE NIET
Henk REESINK
Hans ZAAIJER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Academisch Medisch Centrum Bij de Universiteit van Amsterdam
Original Assignee
F Hoffmann La Roche AG
Academisch Medisch Centrum Bij de Universiteit van Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Academisch Medisch Centrum Bij de Universiteit van Amsterdam filed Critical F Hoffmann La Roche AG
Publication of CA2863106A1 publication Critical patent/CA2863106A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2863106A 2012-02-20 2013-02-18 Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients Abandoned CA2863106A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12156192.2A EP2629096A1 (en) 2012-02-20 2012-02-20 HBV immunocomplexes for response prediction and therapy monitoring of chronic HBV patients
EP12156192.2 2012-02-20
PCT/EP2013/053150 WO2013124229A1 (en) 2012-02-20 2013-02-18 Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients

Publications (1)

Publication Number Publication Date
CA2863106A1 true CA2863106A1 (en) 2013-08-29

Family

ID=47757571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2863106A Abandoned CA2863106A1 (en) 2012-02-20 2013-02-18 Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients

Country Status (7)

Country Link
US (1) US20150192583A1 (enExample)
EP (2) EP2629096A1 (enExample)
JP (1) JP2015508892A (enExample)
CN (1) CN104126124A (enExample)
CA (1) CA2863106A1 (enExample)
HK (1) HK1203616A1 (enExample)
WO (1) WO2013124229A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738319B2 (ja) * 2015-03-30 2020-08-12 雅史 溝上 インターフェロン治療効果予測方法及びそれを用いたｂ型肝炎患者の治療用医薬組成物
HK1250744A1 (zh) * 2015-07-15 2019-01-11 F. Hoffmann-La Roche Ag Hbv治疗应答的生物标志物
US20190339275A1 (en) * 2016-11-11 2019-11-07 Melbourne Health Assay for determining hepatitis b clearance
CN111465703A (zh) * 2017-12-21 2020-07-28 新西兰健康创新中心管理有限公司 分析乙型肝炎病毒突变的方法及其用途
EP3788377A1 (en) * 2018-05-04 2021-03-10 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
CN110564894B (zh) * 2019-09-10 2023-04-07 深圳市罗湖区人民医院 干扰物对荧光定量pcr检测hbv dna的干扰评价方法
CN111474187A (zh) * 2020-04-09 2020-07-31 三峡大学 一种免疫电镜免疫反应盒
CN115466802B (zh) * 2022-10-28 2023-12-12 北京大学 Tp53bp2在调控干扰素信号通路及抗病毒中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726011A (en) * 1994-03-31 1998-03-10 Virginia Commonwealth University Method for diagnosing chronic hepatitis B virus infection
JP2003502384A (ja) * 1999-06-22 2003-01-21 カイロン コーポレイション 慢性ｈｂｖ感染を処置するための方法
CN1261455C (zh) * 2002-07-19 2006-06-28 余宙耀 一种重组人源性抗乙肝表面抗原（HBsAg）Fab抗体及其制取方法
DE10339927A1 (de) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
GB0326416D0 (en) * 2003-11-12 2003-12-17 Karolinska Innovations Ab Methods and means relating to hepatitis B infection
US20090170926A1 (en) * 2004-03-31 2009-07-02 Monash Univeristy Antiviral agents
WO2008135274A2 (de) 2007-05-08 2008-11-13 F. Hoffmann-La-Roche Ag Verfahren zum nachweis spezifischer antikörper der immunglobulinklasse g
EP2419727A1 (en) * 2009-04-14 2012-02-22 Schering Corporation Interferon-alfa sensitivity biomarkers

Also Published As

Publication number Publication date
CN104126124A (zh) 2014-10-29
HK1203616A1 (en) 2015-10-30
EP2629096A1 (en) 2013-08-21
EP2817631A1 (en) 2014-12-31
JP2015508892A (ja) 2015-03-23
US20150192583A1 (en) 2015-07-09
WO2013124229A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
CA2863106A1 (en) Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients
WO2012135573A3 (en) Systems and methods for varying blood flow to identify autoregulatory ranges in a patient
NZ601111A (en) Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
WO2012054588A3 (en) Conduit-containing devices and methods for analyte processing and detection
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2013142796A3 (en) Methods of treatments using ctla4 antibodies
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
MX2016002083A (es) Prediccion y optimizacion de terapia de potasio en suero para terapia de sangre para insuficiencia renal, especialmente hemodialisis domiciliaria.
WO2013158821A3 (en) Methods of treating ankylosing spondylitis using il-17 antagonists
WO2013058640A3 (es) Método de extracción, comprobación y conteo de extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferencia potencializado, específicamente diseñado para su uso como tratamiento contra la enfermedad conocida como asma
HK1205198A1 (en) Prediction of treatment response to jak/stat inhibitor
WO2014179737A3 (en) Assays and methods of treatment relating to vitamin d insufficiency
WO2014181215A3 (en) Method for determining free copper
WO2014018683A3 (en) A novel method to detect resistance to chemotherapy in patients with lung cancer
WO2013043032A3 (es) Extracto dializado de leucocitos de origen bazo de tiburón para la obtención de factor de transferencia potencializado, específicamente diseñado para su uso como inmunomodulador y método de extracción, comprobación y conteo del mismo
IN2014KN00742A (enExample)
WO2013166030A3 (en) Detecting complement activation
WO2011131358A3 (de) Verfahren und vorrichtung zur bestimmung des fistelflusses einer fistel für die dialysebehandlung
WO2012141445A3 (ko) 만성 ｂ형 간질환 환자의 간세포암 발병 위험도 분석 및 예측방법
MY170201A (en) A method for identifying a ganoderma-infected palm tree
WO2014145797A3 (en) Method for treating eclampsia and preeclampsia
MD219Y (en) Method for determining the degree of activity of chronic viral hepatitis C
WO2013144836A3 (en) Device and method for priming a person
Shang et al. Anticoagulant and fibrinolytic disorders in patients with Behcet's disease and recurrent aphthous ulcer
WO2013039374A3 (es) Método de extracción, comprobación y conteo de extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferencia potencializado, específicamente diseñado para su uso como tratamiento contra la enfermedad conocida como vitíligo

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140709

FZDE Discontinued

Effective date: 20180717